A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 1000 participants.
Also called NCT03683186
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,000 participants
- Sponsor
- Registry
-
NCT03683186
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Portugal, Romania, Serbia, Singapore, South Korea, Spain, Sweden, Taiwan, Türkiye, Ukraine, United Kingdom
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT03683186. Allocation not applicable; no masking; primary purpose treatment. Start 2019-09-23 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
- Condition
- PAH
- Condition
- Pulmonary Hypertension
- Condition
- Pulmonary Arterial Hypertension
- Condition
- Hypertension
- Condition
- Connective Tissue Diseases
- Condition
- Familial Primary Pulmonary Hypertension
- Condition
- Vascular Diseases
- Condition
- Cardiovascular Diseases
- Condition
- Hypertension, Pulmonary
- Condition
- Lung Diseases
- Condition
- Respiratory Tract Disease
- Intervention (Drug)
- Ralinepag
- Lead sponsor
- United Therapeutics
Record details
- Record id
cardio:ct-nct03683186- Content hash
794df791e0628041ff56082641067824af5c4d96cc7e2ac9c5bd44e5c3c7bd85